{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal', 'excretion accounted for approximately 6% and 75% of the administered radioactivity,', 'respectively. About 80% of the radioactivity recovered in feces is excreted during the first 48', 'hours as 1 major and 3 minor metabolites with very small amounts (less than 8%) of unchanged', 'drug', '3.2.2', 'Pharmaceutical Properties and Formulation', 'Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by', 'semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew', 'plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl', 'ester, 13-ester with 5\u00df-20-epoxy-1,2a,4,78,108,13a-hexahydroxytax-11-en-9-one 4-acetate 2-', 'benzoate, trihydrate. Docetaxel is a white to almost-white powder with an empirical formula', 'of', 'C43H53NO14 3H2O, and a molecular weight of 861.9. It is highly lipophilic and', 'practically insoluble in water', '3.2.3', 'Clinical Safety', 'The following data are based on the experience of 332 prostate cancer patients, who were', 'treated with TAXOTERE 75 mg/m\u00b2 every 3 weeks in combination with prednisone 5 mg orally', 'twice daily:', '2', 'TAXOTERE 75 mg/m', 'Mitoxantrone 12 mg/m\u00b2', 'every 3 weeks +', 'every 3 weeks +', 'prednisone 5 mg twice', 'prednisone 5 mg twice', 'daily', 'daily', 'n=332', 'n=335', '%', '%', 'Adverse Reaction', 'Any', 'Grade 3/4', 'Any', 'Grade 3/4', 'Anemia', '67', '5', '58', '2', 'Neutropenia', '41', '32', '48', '22', 'Thrombocytopenia', '3', '1', '8', '1', 'Febrile neutropenia', '3', 'N/A', '2', 'N/A', 'Infection', '32', '6', '20', '4', 'Epistaxis', '6', '0', '2', '0', 'Allergic Reactions', '8', '1', '1', '0', 'Fluid Retention*', '24', '1', '5', '0', 'Weight Gain*', '8', '0', '3', '0', 'Peripheral Edema*', '18', '0', '2', '0', 'Neuropathy Sensory', '30', '2', '7', '0', 'Neuropathy Motor', '7', '2', '3', '1', 'Rash/Desquamation', '6', '0', '3', '1', 'Alopecia', '65', 'N/A', '13', 'N/A', 'Nail Changes', '30', '0', '8', '0', 'Page 14 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '2', 'TAXOTERE 75 mg/m', 'Mitoxantrone 12 mg/m', 'every 3 weeks +', 'every 3 weeks +', 'prednisone 5 mg twice', 'prednisone 5 mg twice', 'daily', 'daily', 'n=332', 'n=335', '%', '%', 'Adverse Reaction', 'Any', 'Grade 3/4', 'Any', 'Grade 3/4', 'Nausea', '41', '3', '36', '2', 'Diarrhea', '32', '2', '10', '1', 'Stomatitis/Pharyngitis', '20', '1', '8', '0', 'Taste Disturbance', '18', '0', '7', '0', 'Vomiting', '17', '2', '14', '2', 'Anorexia', '17', '1', '14', '0', 'Cough', '12', '0', '8', '0', 'Dyspnea', '15', '3', '9', '1', 'Cardiac left ventricular', '10', '0', '22', '1', 'function', 'Fatigue', '53', '5', '35', '5', 'Myalgia', '15', '0', '13', '1', 'Tearing', '10', '1', '2', '0', 'Arthralgia', '8', '1', '5', '1', '*Related to treatment', '3.3', 'Abiraterone Acetate (Abiraterone)', 'Abiraterone is an inhibitor of CYP17 (17a-hydroxylase/C17,20-lyase)', \"Abiraterone for this trial will be dispensed as part of the patient's standard of care therapy.\", 'Depending on insurance and/or physician preference, Zytiga, Yonsa, or a generic abiraterone', 'acetate will be allowed. Dosing for each regimen should be consistent with FDA prescribing', 'information.', 'Refer to Package Insert for detail regarding clinical administration of Zytiga, Yonsa, or generic', 'abiraterone acetate. The following information is taken from these documents:', '3.3.1', 'Pharmacology', 'Abiraterone acetate (abiraterone) is converted in vivo to abiraterone, an androgen biosynthesis', 'inhibitor, that inhibits 17 a-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in', 'testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.', 'CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone', 'to their 17-hydroxy derivatives by 17a-hydroxylase activity and 2) the subsequent formation', 'of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase', 'activity. DHEA and androstenedione are androgens and are precursors of testosterone.', 'Page 15 of 52']\n\n###\n\n", "completion": "END"}